The results of a recent study investigating the injectable Aquamid were revealed at The American Society of Dermatologic Surgery (ASDS) 2009 meeting.
Aquamid is an injectable filler designed to treat fine lines and wrinkles, and is made with 2.5% polyacrylamide hydrogel and, according to the results of the study, is as well tolerated as hyaluronic acid fillers such as Restylane and Juvederm.
Rhoda Narins, MD, Clinical Professor of Dermatology of the New York University School of Medicine in New York City and Director of the Dermatology Surgery and Laser Center of New York reports that, “our results demonstrate that polyacrylamide hydrogel shows strong potential as a permanent soft tissue filler.” The ingredients in Aquamid are non-biodegradable, which means this particular filler cannot migrate. The compound is also expected to last longer than traditional hyaluronic fillers, which may be a cost benefit to consumers.
Aquamid is marketed as a soft volume filler to enhance facial contours, fill out nasolabial folds, smooth out wrinkles and folds in the cheeks and lips, and can also be used to reshape the nose. The filler boasts natural-looking results and lasting satisfaction. In long-term clinical trials, physicians judged the aesthetic results at one, two and four year intervals, and found that results were still good or very good for more than 90% of patients at each interval.
Data after five years shows that patients were either very satisfied or satisfied with results during the follow-up session, and the filler produced similar aesthetic results. The filler is designed to completely integrate with the body’s tissues, which means there is no risk of an allergic reaction to the micro-particles present in the compound. Aquamid is also not linked to tissue hardening or fibrosis.
Efficacy of Aquamid was maintained through the 12-month post follow up treatment for the filler, and showed a significant improvement in results in treatment groups.